How many drug targets are there? JP Overington, B Al-Lazikani, AL Hopkins Nature reviews Drug discovery 5 (12), 993-996, 2006 | 4604 | 2006 |
ChEMBL: a large-scale bioactivity database for drug discovery A Gaulton, LJ Bellis, AP Bento, J Chambers, M Davies, A Hersey, Y Light, ... Nucleic acids research 40 (D1), D1100-D1107, 2012 | 4193 | 2012 |
A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ... Nature reviews Drug discovery 16 (1), 19-34, 2017 | 2202 | 2017 |
The genome of the blood fluke Schistosoma mansoni M Berriman, BJ Haas, PT LoVerde, RA Wilson, GP Dillon, GC Cerqueira, ... Nature 460 (7253), 352-358, 2009 | 1213 | 2009 |
Standard conformations for the canonical structures of immunoglobulins B Al-Lazikani, AM Lesk, C Chothia Journal of molecular biology 273 (4), 927-948, 1997 | 1174 | 1997 |
Combinatorial drug therapy for cancer in the post-genomic era B Al-Lazikani, U Banerji, P Workman Nature biotechnology 30 (7), 679-692, 2012 | 1110 | 2012 |
Therapeutic opportunities within the DNA damage response LH Pearl, AC Schierz, SE Ward, B Al-Lazikani, FMG Pearl Nature Reviews Cancer 15 (3), 166-180, 2015 | 552 | 2015 |
Defective acute inflammation in Crohn's disease: a clinical investigation DJB Marks, MWN Harbord, R MacAllister, FZ Rahman, J Young, ... The Lancet 367 (9511), 668-678, 2006 | 524 | 2006 |
Genomic-scale prioritization of drug targets: the TDR Targets database F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ... Nature reviews Drug discovery 7 (11), 900-907, 2008 | 362 | 2008 |
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance D Gonzalez de Castro, PA Clarke, B Al‐Lazikani, P Workman Clinical Pharmacology & Therapeutics 93 (3), 252-259, 2013 | 309 | 2013 |
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ... Nature genetics 50 (5), 682-692, 2018 | 238 | 2018 |
Protein structure prediction B Al-Lazikani, J Jung, Z Xiang, B Honig Current opinion in chemical biology 5 (1), 51-56, 2001 | 203 | 2001 |
Drug discovery in advanced prostate cancer: translating biology into therapy TA Yap, AD Smith, R Ferraldeschi, B Al-Lazikani, P Workman, ... Nature reviews Drug discovery 15 (10), 699-718, 2016 | 156 | 2016 |
Objective assessment of cancer genes for drug discovery MN Patel, MD Halling-Brown, JE Tym, P Workman, B Al-Lazikani Nature reviews Drug discovery 12 (1), 35-50, 2013 | 155 | 2013 |
Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation C Abad-Zapatero, O Perišić, J Wass, AP Bento, J Overington, ... Drug discovery today 15 (19-20), 804-811, 2010 | 125 | 2010 |
Large-scale profiling of kinase dependencies in cancer cell lines J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ... Cell reports 14 (10), 2490-2501, 2016 | 121 | 2016 |
canSAR: an updated cancer research and drug discovery knowledgebase JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ... Nucleic acids research 44 (D1), D938-D943, 2016 | 106 | 2016 |
Minimum information about a bioactive entity (MIABE) S Orchard, B Al-Lazikani, S Bryant, D Clark, E Calder, I Dix, O Engkvist, ... Nature reviews Drug discovery 10 (9), 661-669, 2011 | 106 | 2011 |
canSAR: updated cancer research and drug discovery knowledgebase KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani Nucleic acids research 42 (D1), D1040-D1047, 2014 | 102 | 2014 |
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells ZS Walters, B Villarejo-Balcells, D Olmos, TWS Buist, E Missiaglia, ... Oncogene 33 (9), 1148-1157, 2014 | 99 | 2014 |